Cargando…

In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer

The activity of drug transporters is central to the secretory function of the kidneys and a defining feature of renal proximal tubule epithelial cells (RPTECs). The expression, regulation, and function of these membrane-bound proteins is well understood under normal renal physiological conditions. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Caetano-Pinto, Pedro, Justian, Nathanil, Dib, Maria, Fischer, Jana, Somova, Maryna, Burchardt, Martin, Wolff, Ingmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456511/
https://www.ncbi.nlm.nih.gov/pubmed/36077583
http://dx.doi.org/10.3390/ijms231710177
_version_ 1784785833098739712
author Caetano-Pinto, Pedro
Justian, Nathanil
Dib, Maria
Fischer, Jana
Somova, Maryna
Burchardt, Martin
Wolff, Ingmar
author_facet Caetano-Pinto, Pedro
Justian, Nathanil
Dib, Maria
Fischer, Jana
Somova, Maryna
Burchardt, Martin
Wolff, Ingmar
author_sort Caetano-Pinto, Pedro
collection PubMed
description The activity of drug transporters is central to the secretory function of the kidneys and a defining feature of renal proximal tubule epithelial cells (RPTECs). The expression, regulation, and function of these membrane-bound proteins is well understood under normal renal physiological conditions. However, the impact of drug transporters on the pathophysiology of kidney cancer is still elusive. In the present study, we employed different renal cell carcinoma (RCC) cell lines and a prototypical non-malignant RPTEC cell line to characterize the activity, expression, and potential regulatory mechanisms of relevant renal drug transporters in RCC in vitro. An analysis of the uptake and efflux activity, the expression of drug transporters, and the evaluation of cisplatin cytotoxicity under the effects of methylation or epidermal growth factor receptor (EGFR) inhibition showed that the RCC cells retained substantial drug transport activity. In RCC cells, P-glycoprotein was localized in the nucleus and its pharmacological inhibition enhanced cisplatin toxicity in non-malignant RPTECs. On the other hand, methylation inhibition enhanced cisplatin toxicity by upregulating the organic cation uptake activity in RCC cells. Differential effects of methylation and EGFR were observed in transporter expression, showing regulatory heterogeneity in these cells. Interestingly, the non-malignant RPTEC cell line that was used lacked the machinery responsible for organic cation transport, which reiterates the functional losses that renal cells undergo in vitro.
format Online
Article
Text
id pubmed-9456511
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94565112022-09-09 In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer Caetano-Pinto, Pedro Justian, Nathanil Dib, Maria Fischer, Jana Somova, Maryna Burchardt, Martin Wolff, Ingmar Int J Mol Sci Article The activity of drug transporters is central to the secretory function of the kidneys and a defining feature of renal proximal tubule epithelial cells (RPTECs). The expression, regulation, and function of these membrane-bound proteins is well understood under normal renal physiological conditions. However, the impact of drug transporters on the pathophysiology of kidney cancer is still elusive. In the present study, we employed different renal cell carcinoma (RCC) cell lines and a prototypical non-malignant RPTEC cell line to characterize the activity, expression, and potential regulatory mechanisms of relevant renal drug transporters in RCC in vitro. An analysis of the uptake and efflux activity, the expression of drug transporters, and the evaluation of cisplatin cytotoxicity under the effects of methylation or epidermal growth factor receptor (EGFR) inhibition showed that the RCC cells retained substantial drug transport activity. In RCC cells, P-glycoprotein was localized in the nucleus and its pharmacological inhibition enhanced cisplatin toxicity in non-malignant RPTECs. On the other hand, methylation inhibition enhanced cisplatin toxicity by upregulating the organic cation uptake activity in RCC cells. Differential effects of methylation and EGFR were observed in transporter expression, showing regulatory heterogeneity in these cells. Interestingly, the non-malignant RPTEC cell line that was used lacked the machinery responsible for organic cation transport, which reiterates the functional losses that renal cells undergo in vitro. MDPI 2022-09-05 /pmc/articles/PMC9456511/ /pubmed/36077583 http://dx.doi.org/10.3390/ijms231710177 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Caetano-Pinto, Pedro
Justian, Nathanil
Dib, Maria
Fischer, Jana
Somova, Maryna
Burchardt, Martin
Wolff, Ingmar
In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer
title In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer
title_full In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer
title_fullStr In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer
title_full_unstemmed In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer
title_short In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer
title_sort in vitro characterization of renal drug transporter activity in kidney cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456511/
https://www.ncbi.nlm.nih.gov/pubmed/36077583
http://dx.doi.org/10.3390/ijms231710177
work_keys_str_mv AT caetanopintopedro invitrocharacterizationofrenaldrugtransporteractivityinkidneycancer
AT justiannathanil invitrocharacterizationofrenaldrugtransporteractivityinkidneycancer
AT dibmaria invitrocharacterizationofrenaldrugtransporteractivityinkidneycancer
AT fischerjana invitrocharacterizationofrenaldrugtransporteractivityinkidneycancer
AT somovamaryna invitrocharacterizationofrenaldrugtransporteractivityinkidneycancer
AT burchardtmartin invitrocharacterizationofrenaldrugtransporteractivityinkidneycancer
AT wolffingmar invitrocharacterizationofrenaldrugtransporteractivityinkidneycancer